Formulation, Development and Stability of Granisetron Sustained Release Oral Dispersible Tablets

Formulation and Evaluation of Sustained Release Matrix Tablets of Glipizide

      The purpose of this study was to develop a new monolithic matrix tablet to completely deliver glipizide in a zero order manner over a sustained period. Two approaches were examined using drug in a formulation that contain polymer like hydroxylpropyl methyl-cellulose K 100 (HPMCK) and Eudragit L 100. The granules were prepared by wet granulation method and thereby formulated as F-1, F-2. F...

formulation and evaluation of sustained release matrix tablets of glipizide

the purpose of this study was to develop a new monolithic matrix tablet to completely deliver glipizide in a zero order manner over a sustained period. two approaches were examined using drug in a formulation that contain polymer like hydroxylpropyl methyl-cellulose k 100 (hpmck) and eudragit l 100. the granules were prepared by wet granulation method and thereby formulated as f-1, f-2. f-3 and...

Formulation, release and stability study of Bupropion sustained release 150 mg using Hydroxypropylmethylcellulose (HPMC) 4000cps basis

In this study,formulation of sustained-releasingmatrix tablet of bupropion 150 mg, using hydroxypropylmethylcellu lose(HPMC) 4000cps was evaluatedwith the aim of reducing the frequency of daily dose. The level of HPMC4000 ,polyvinylpyrolidone(PVP) and magnesium stearate(Mg St)was varied based on a 2level 3 factor factorial experimental designusing the release rate of the drug from the matrices ...

Formulation and Evaluation of Sustained Release Tablets Using Prunus armeniaca (L.) and Prunus domestica (L.) Gums

Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron.

Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, palonosetron, for CINV prevention in some chemotherapy regimens. A new granisetron formulation, APF530, has been developed as an alternative long-acting agent. APF530 utili...